Sign In to Follow Application
View All Documents & Correspondence

Substituted 6,7 Dihydro 5 H Benzo[7]Annulene Compounds And Their Derivatives, Processes For Their Preparation And Therapeutic Uses Thereof

Abstract: Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; R4 and R5 represent a hydrogen atom, a halogen atom, a -IMH2 group, a (C1- C3)alkyl group, a (C1-C3)alkoxy group, or a -OH group; or R4 and R5 together form an oxo group or R4 and R5 together form a =NOCH3 group or a (C3-C5)cycloalkyl group; R7 represents a hydrogen atom, a methyl group, a -OH group or a fluorine atom; R6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 3 to 8 membered-heterocycloalkyl group, a (C1-C6)alkyl group or a phenyl (C1- C2) alkyl group; X represents - CH2-, -O- or -S-; Y represents -CH=, - N= or -CR" =; R8 represents a (C1-C3) alkyl group, a halogen atom, a cyano group, or a (C1-C3) fluoroalkyl group; R9 represents a hydrogen atom or a fluorine atom; RIO and RIO'represent a hydrogen atom or a fluorine atom; Rll represents a hydrogen atom a (C1-C3)alkyl group or a cyclopropyl group; n is 0, 1 or 2, and m is 0 or 1. Further disclosed are process for preparing the same, pharmaceutical compositions comprising them as well as said compounds of formula (I) for use as an inhibitor and degrader of estrogen receptors, in particular in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
15 May 2023
Publication Number
31/2024
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application

Applicants

SANOFI
46 avenue de la Grande Armée 75017 Paris

Inventors

1. BERNARDELLI, Patrick
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
2. BIANCIOTTO, Marc
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
3. CERTAL, Victor
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
4. DA ROCHA, Alice
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
5. DE BRUIN, Béatrice
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
6. EL AHMAD, Youssef
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
7. HALLEY, Frank
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
8. MOUGENOT, Patrick
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
9. NICOLAI, Eric
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
10. PERIERS, Anne-Marie
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
11. PETIT, Frédéric
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
12. SLOWINSKI, Franck
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris
13. TERRIER, Corinne
c/o Sanofi, Patent Department 54, rue la Boétie 75008 Paris

Specification

Documents

Application Documents

# Name Date
1 202317033960.pdf 2023-05-15
2 202317033960-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [15-05-2023(online)].pdf 2023-05-15
3 202317033960-STATEMENT OF UNDERTAKING (FORM 3) [15-05-2023(online)].pdf 2023-05-15
4 202317033960-FORM 1 [15-05-2023(online)].pdf 2023-05-15
5 202317033960-DECLARATION OF INVENTORSHIP (FORM 5) [15-05-2023(online)].pdf 2023-05-15
6 202317033960-COMPLETE SPECIFICATION [15-05-2023(online)].pdf 2023-05-15
7 202317033960-Proof of Right [24-07-2023(online)].pdf 2023-07-24
8 202317033960-FORM-26 [24-07-2023(online)].pdf 2023-07-24
9 202317033960-FORM 18 [30-09-2024(online)].pdf 2024-09-30